SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Senti Bio’s Co-Founder and Chief Executive Officer of Senti, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. As part of the event, Dr. Lu dove deeper into his dedicat ...

Core Insights - Senti Bio is presenting its innovative logic-gated CAR-NK cell therapy, which targets leukemic cells while preserving healthy bone marrow [1] - The presentation will take place at the BioScience Forum on July 23, 2025, featuring Dr. Kanya Rajangam as the speaker [2] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][4] - The company aims to create therapies that can precisely kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing control post-administration [4] - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting both liquid and solid tumors, with preclinical evidence supporting their efficacy in NK and T cells [4]

Core Insights - Senti Biosciences, Inc. has appointed Bryan Baum to its Board of Directors, enhancing its leadership team with his extensive entrepreneurial and investment experience [1][3][4] - Bryan Baum is recognized for his successful track record in scaling companies and has invested in notable firms such as SpaceX, OpenAI, and Airbnb, which may provide strategic advantages to Senti Bio [2][3] - The company is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, aiming to address cancer treatments that current drugs cannot [3][5] Company Overview - Senti Bio is a clinical-stage biotechnology company that leverages synthetic biology to engineer Gene Circuits for new medicines, targeting incurable diseases [5] - The company's pipeline includes cell therapies designed to specifically target and kill cancer cells while sparing healthy cells, with preclinical evidence supporting their efficacy in both NK and T cells [5] - Senti Bio is also exploring the potential of Gene Circuits in other disease modalities beyond oncology, indicating a broad scope for future development [5]

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference, highlighting its innovative approach to tumor-specific therapies [1] Company Overview - Senti Bio is dedicated to creating new cell and gene therapies for patients with incurable diseases, utilizing synthetic biology to engineer Gene Circuits for enhanced precision and control [3] - The company's pipeline includes cell therapies designed to target both liquid and solid tumors, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [3] Conference Details - The SEED Conference, established in 2014, serves as a premier event for synthetic biologists, facilitating networking and collaboration among over 5,000 professionals in the field [1] - Senti Bio's presentation will focus on "Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated Cells," showcasing its advancements in the field [1]

Core Insights - Senti Biosciences, Inc. is participating in a Virtual Fireside Chat hosted by Chardan Capital Markets on June 9, 2025, featuring key executives discussing the company's advancements in biotechnology [1][2]. Company Overview - Senti Biosciences is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3]. - The company aims to create therapies that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for controllability post-administration [3]. - Senti's pipeline includes cell therapies engineered with Gene Circuits targeting both liquid and solid tumors, with preclinical evidence supporting their efficacy in NK and T cells [3]. Additional Information - For further details, Senti Biosciences encourages stakeholders to visit their official website and follow their social media channels for updates and disclosures [4].

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [3] - The company aims to create new medicines that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [3] Upcoming Event - Timothy Lu, M.D., Ph.D., Co-Founder and CEO of Senti Bio, will present at the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on May 29, 2025, at 2:40 PM ET [1][2] Technology and Pipeline - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting challenging liquid and solid tumor indications [3] - The Gene Circuits have shown preclinical efficacy in both NK and T cells, with potential applications extending beyond oncology [3]

Core Insights - Senti Biosciences, Inc. announced positive preliminary clinical results for its lead program, SENTI-202, targeting Relapsed/Refractory AML [1] - The company will present these results at the Citizens JMP Life Sciences Conference on May 8, 2025, in New York [1][2] - Senti Bio is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [3] Company Overview - Senti Bio is a clinical-stage biotechnology company dedicated to creating innovative cell and gene therapies for patients with incurable diseases [3] - The company utilizes a synthetic biology platform to engineer Gene Circuits that enhance precision and control in targeting cancer cells while sparing healthy cells [3] - Senti Bio's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [3]